Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial.
autologous stem cell transplantation
cost-effectiveness analysis
lymphoma
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
17 03 2021
17 03 2021
Historique:
received:
14
01
2021
revised:
10
02
2021
accepted:
11
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
25
9
2021
Statut:
epublish
Résumé
We conducted an analysis of indirect costs alongside the LY.12 randomized trial in patients with relapsed or refractory (R/R) aggressive non-Hodgkin lymphoma (NHL). Lost productivity data for Canadian patients and caregivers in the trial were collected at baseline and with each chemotherapy cycle pre-transplant, using an adapted Lost Productivity questionnaire. Mean per patient indirect costs were CAD 2999 for patients in the GDP arm and CAD 3400 in the DHAP arm. A substantial majority was not working or had to reduce their workload during this treatment time. Salvage chemotherapy for R/R aggressive NHL is associated with significant indirect costs to patients and their caregivers.
Identifiants
pubmed: 33802634
pii: curroncol28020119
doi: 10.3390/curroncol28020119
pmc: PMC8025821
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1256-1261Références
Breast Cancer Res Treat. 2011 Nov;130(1):235-42
pubmed: 21567238
J Clin Oncol. 2014 Nov 1;32(31):3490-6
pubmed: 25267740
N Engl J Med. 1995 Dec 7;333(23):1540-5
pubmed: 7477169
Leuk Lymphoma. 2016 Nov;57(11):2636-43
pubmed: 27077242
Haematologica. 2005 Oct;90(10):1422-32
pubmed: 16219580
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
J Natl Cancer Inst. 2015 Apr 13;107(7):
pubmed: 25868579